SCHEMBL3947263

SCHEMBL3947263

COc1cc2ncnc(Nc3nc4ccc(NC(=O)Nc5ccccc5)cc4s3)c2cc1OC

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.72
EGFR P00533 8/20 0.64
KIT P10721 1/20 0.62
AURKA O14965 3/20 0.59
AURKB Q96GD4 1/20 0.59
MAPK14 Q16539 1/20 0.57
CSF1R P07333 2/20 0.56
RET P07949 1/20 0.56
LCK P06239 1/20 0.55
MEN1 O00255 1/20 0.55
NPC1 O15118 1/20 0.55
LMNA P02545 1/20 0.55
POLB P06746 1/20 0.55
MAPT P10636 1/20 0.55
NFKB1 P19838 1/20 0.55
RAB9A P51151 1/20 0.55
NFKB2 Q00653 1/20 0.55
KMT2A Q03164 1/20 0.55
RELA Q04206 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3949246 0.92 KDR (0.60) KDREGFRKITAURKAAURKB
SCHEMBL3946532 0.92 KDR (0.74) KDREGFRKITRETMEN1
SCHEMBL3953259 0.92 KDR (0.63) KDREGFRKITHDAC6
SCHEMBL3947784 0.91 EGFR (0.61) KDREGFRKITAURKAAURKB
SCHEMBL3947988 0.90 AURKB (0.71) KDREGFRAURKAAURKBMAPK14
SCHEMBL3954616 0.89 EGFR (0.62) KDREGFRKITMAPK14
SCHEMBL3954129 0.88 KDR (0.72) KDREGFRAURKAAURKBMAPK14
SCHEMBL3946804 0.87 EGFR (0.78) KDREGFRAURKAAURKB
SCHEMBL3945407 0.87 KDR (0.54) KDREGFRKIT
SCHEMBL3948976 0.85 BRAF (0.60) KDREGFRKITAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514460-B2 Benzazole analogues and uses thereof 4SC AG (DE) 2009-04-07 US disclosed
US-7514460-B2 Benzazole analogues and uses thereof 4SC AG (DE) 2009-04-07 US disclosed
US-7514460-B2 Benzazole analogues and uses thereof 4SC AG (DE) 2009-04-07 US disclosed
EP-1885719-A1 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS 4SC AG (DE) 2008-02-13 EP disclosed
WO-2006066795-A1 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS 4SC AG (DE) 2006-06-29 WO disclosed
EP-1674467-A1 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors 4SC AG (DE) 2006-06-28 EP disclosed
US-20060135782-A1 Benzazole analogues and uses thereof 4SC AG (DE) 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135782-A1 Benzazole analogues and uses thereof DCK, SBK3, DAPK3 KDR 1657/4885EGFR 437/4885KIT 1709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.